3840.T) announced today that its subsidiary RMDC has entered into a strategic partnership with Korean">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from PATH Corporation was processed by Pulse News Wire on March 9, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

PATH Corporation (3840.T) Forms Strategic Partnership with Korean Biotech Firm MediPost

TOKYO, Mar 09 (Pulse News Wire) – PATH Corporation (3840.T) announced today that its subsidiary RMDC has entered into a strategic partnership with Korean biotechnology firm MediPost Co., Ltd. The agre

View all 3840.T disclosures →

Share this disclosure: Share on X Share on LinkedIn